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ABSTRACT
Chronic granulomatous disease 
(CGD) is a primary immune de-
ﬁciency disorder of the phago-
cytes. In this disorder, phago-
cytic cells (polymorphonuclear 
leukocytes and monocytes) can-
not produce active oxygen me-
tabolites and, therefore, cannot 
destroy the ingested intracellular 
bacteria. Clinically, patients with 
CGD usually have recurrent bac-
terial and fungal infections caus-
ing abscess and granuloma for-
mation in the skin, lymph nodes 
and visceral organs.
In this report, we present a boy 
from Libya with a rare autosomal 
recessive trait of CGD (defect of 
p22-phox) who has chronic lung 
disease following multiple severe 
pneumonia attacks. The case we 
present suffered from bloody di-
arrhea since the third month of     www.ljm.org.ly   
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his life. He also had recurrent 
episodes of fever, and later, de-
veloped persistent cervical lym-
phadenitis and failure to gain 
weight. CGD is a very rare condi-
tion worldwide. It is also not rec-
ognized here in Libya, and usu-
ally not in the list of differential 
diagnosis for chronic pulmonary 
infections. We advise that pedia-
tricians and general practitioners 
who treat chronic cases of lung 
diseases (with or without chronic 
diarrhea) should consider prima-
ry immunodeﬁciency disorders in 
the hope that early diagnosis and 
treatment may prevent chronic 
complications especially of the 
respiratory tract. Furthermore, 
we state that, to the best of our 
knowledge, this is the ﬁrst docu-
mented case of CGD from Libya.
INTRODUCTION
Chronic granulomatous disease 
is a hereditarily determined ill-
ness, characterized by inability 
of the body’s phagocytic cells to 
destroy certain microorganisms. 
As a consequence, patients with 
CGD have an increased suscep-
tibility to infections caused by cer-
tain bacteria and fungi (frequently 
Staphylococcus aureus, and As-
pergillus species, respectively) 
[1]. This insufﬁciency in microbial 
killing is usually caused by a defect 
in the nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxi-
dase enzyme complex. NADPH 
is the enzyme that generates the 
microbicidal respiratory burst [2, 
3]. The deﬁciencies of oxidative 
metabolism are usually detected 
with either the nitroblue tetrazo-
lium (NBT) dye test or the dihy-
drorhodamine (DHR) oxidation 
test. These tests are based on 
the ability of products of oxidative 
metabolism to alter the oxidation 
states of reporter molecules so 
that they can be detected micro-
scopically (in the case of NBT) or 
by ﬂow cytometry (in the case of 
DHR) [4]. However, NBT test, al-
though more conventionally used, 
is sometimes not sufﬁciently sen-
sitive. Therefore, many investiga-
tors have preferred the use of the 
DHR test [5].
In CGD, phagocytes manage to 
ingest bacteria normally; how-
ever they can not destroy them. 
Patients usually have an elevated 
incidence of mucosal inﬂamma-
tory disorders such as colitis, en-
teritis, and gastric outlet obstruc-
tion. A cutaneous disease occurs 
in 60-70% of patients. CGD is an 
extremely rare disease that oc-
curs in about 1 in every quarter of 
a million live births [6].Libyan Journal of Medicine, Volume 1, 2006
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CASE REPORT
A Libyan boy ﬁrst presented to the 
pediatrics department of Tripoli 
Medical Centre (Libya) when he 
was 3 months old suffering from 
loose stool with streaks of blood. 
He also had frequent episodes 
of fever at ﬁrst presentation to 
the hospital; later, he developed 
persistent cervical lymphadeni-
tis and failed to gain weight. The 
boy is the 3rd child (of 4 children) 
from related Libyan parents. He 
was born in the 35th week of ges-
tation with a birth weight of 2400 
grams. He was vaccinated with 
BCG on the second day of his 
life. The ﬁrst child of the family (a 
girl) had a similar medical history, 
with persisting pneumonia, sus-
pected tuberculosis, and anemia. 
She died in Libya in 2004. The 
patient’s older brother is normal. 
However, his younger sister was 
found to be a carrier of the dis-
ease; but otherwise healthy and 
has no signiﬁcant susceptibility to 
infections up to the present date.
The patient presented to the 
University Children’s Hospital of 
Bonn (Germany) at the age of 10 
months; and because of a posi-
tive tuberculin skin test and pre-
vious history of BCG vaccination, 
an infection with BCG was sus-
pected. He was put on antimyco-
bacterial regimen (rifampicin and 
isoniazid). The patient was later 
transferred to Charite Children’s 
Hospital of Berlin to continue his 
treatment, and further investiga-
tions were carried out. A lymph 
node of the left axilla was surgi-
cally removed, and a culture from 
the biopsy grew bacteria. Addi-
tionally, cytomegalovirus (CMV) 
was detected in the urine without 
apparent disease. These ﬁndings 
have lead to a suspicion of a pri-
mary immune deﬁciency disor-
der. 
At the age of 12 months, he 
again showed recurrent episodes 
of pneumonia, diarrhea and en-
largement of lymph nodes. He 
was treated with antibiotics sev-
eral times, with good results. A 
few months later, following an im-
munological proﬁle for his case, 
a negative NBT and DHR assay 
was detected. The ﬁnal diagno-
sis of chronic granulomatous dis-
ease was conﬁrmed by molecular 
analysis, which revealed a defect 
in the p22-phox component of the 
CYBA gene.
The results of his investigations 
were as follows: Stool analysis 
revealed the presence of Clostrid-
ium difﬁcile; however, no para-
sites were found. CMV DNA was 
present in urine. But the aspergil-    www.ljm.org.ly   
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lus antigen was not detected in his 
blood. The excised cervical lymph 
nodes (LN) yielded the growth of 
Enterococcus faecalis and Kleb-
siella pneumoniae on culture. 
There was no growth of myco-
bacteria on culture of ﬂuids from 
the bronchial lavage performed. 
Gastroduodenoscopy and colos-
copy showed redness and swell-
ing of the mucous membrane of 
the stomach and the colon, re-
spectively. Furthermore, signs of 
colitis and tendency for superﬁcial 
bleeding were evident. 
Immunoglobulin levels against 
tetanus, diphtheria and pertus-
sis (DPT) were normal. 
Serum antibody levels 
were as follows: IgG 1697 
mg/dl, IgA 161 mg/dl, IgM 
100 mg/dl. Indicating that 
humoral immunity of the 
patient was functioning 
normally. His haemoglobin 
level was moderately low 
(9.9 g/dl). Normal values 
were detected for sodium, 
potassium, calcium, chlo-
ride, creatinine, transami-
nases, LDH and alkaline 
phosphatase.
Ultrasound imaging (USI) showed 
enlarged cervical LN (maximum 
diameter 22 mm), and slightly en-
larged mesenteric LN (11 mm). 
Furthermore, the liver was mod-
erately enlarged (Figure 1). 
X-rays of the chest showed that 
the left diaphragm was lower than 
the right, and the left lung was 
smaller than the right, with cen-
tral inﬁltrates on both sides. The 
heart was shown to be displaced 
to the left side. 
A high-resolution computed tom-
ography (CT) scan of the chest 
conﬁrmed the X-ray readings and 
showed hypoplastic left lung with 
diffuse dystelectasis; however, 
no other speciﬁc inﬁltrates were 
found (Figure 2).
Figure 1:  Ultrasound image showing a 
mild hepatomegaly.
Magnetic resonance imaging 
(MRI) of the chest conﬁrmed the Libyan Journal of Medicine, Volume 1, 2006
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USI ﬁndings and revealed mul-
tiple enlarged cervical LN, and 
one large mediastinal LN on the 
right side in addition to a nonspe-
ciﬁc mass situated on the right 
paravertebral area at the level of 
chest vertebral body number 11 
and 12.
Figure 2: High-resolution CT-scan 
showing a left hypoplastic lung.
Positron emission tomography 
(PET) showed focally intense sig-
nals of the upper lobe of the right 
lung (paravertebrally) and in the 
glandula submandibularis (cervi-
cal LN), and a less intense signal 
in the inferior lobe of the left lung 
(Figure 3). 
PET-CT Fusion technique [7] 
which allows accurate correlation 
of great anatomic details (from 
the CT scan) and informative 
metabolic information (from the 
PET scan) was used, and it con-
ﬁrmed the CT scan ﬁndings (Fig-
ure 4). Genetic analysis of the pa-
tient’s NADPH oxidase revealed 
a deletion of 7 base pairs (bp) in 
exon 5 on both alleles of 
the p22-phox gene. The 
bp deleted were from 323 
to 329 (the investigation 
was done in Dresden, 
Germany).
DISCUSSION
The exact incidence of 
CGD is unknown. In the 
USA, it is estimated that 
CGD affects  approxi-
mately one infant per 
quarter of a million live 
births [6, 8]. Worldwide, 
however, the incidence of the 
disease varies among the popu-
lations studied, with variations 
from 1 case per 160 thousands 
individuals to 1 case per 1 million 
people [9]. Surprisingly, for Libya, 
and after a thorough literature 
search, we conﬁrm that this is the 
ﬁrst reported case of CGD.
Four genes have been connected 
to CGD¨Dthe CYBB gene, encod-
ing the gp91-phox subunit; the 
CYBA gene, encoding for p22-    www.ljm.org.ly   
page
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phox; the NCF1 gene, encoding 
p47-phox; and the NCF2 gene 
which encodes for p67-phox. 
Figure 3: PET image showing intense 
signals on the upper lobe of the right 
lung (yellow arrow).
Figure 4: PET-CT Fusion scan show-
ing the location of the focally intense 
signals from the upper lobe of the right 
lung paravertebrally, and the less in-
tense signals from the left lung, indicat-
ing a hypoplastic left lung. 
CGD is frequently inherited (60% 
of cases) in an X-linked reces-
sive manner where most pa-
tients are boys, who have 
hemizygous mutations on 
the X-linked gene coding 
for gp91-phox. However, 
among the other subtypes 
of CGD, the autosomal 
recessive forms (40% of 
cases) may be associ-
ated with milder disease. 
The extent to which en-
vironmental factors and 
secondary genetic de-
fects may inﬂuence the 
course of the disease is still not 
understood [10, 11]. 
A wide variety of molecular de-
fects have been de-
scribed in the genes for 
the gp91-phox compo-
nent, the p22-phox com-
ponent, and the p67-
phox component. These 
defects include frame 
shifts; deletions; and non-
sense, missense, splice-
region, and regulatory re-
gion mutations [11]. The 
protien, p40-phox, has 
been involved in the regulation 
of the NADPH oxidase, but no 
individual with a mutation in this 
protein has been found so far. 
A new variant of CGD has been 
described; this form is caused by 
an inhibitory mutation in Rac2, Libyan Journal of Medicine, Volume 1, 2006
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which regulates activity of the 
neutrophil respiratory burst and 
actin assembly.  Mutations in the 
genes for p67-phox (NCF2) and 
p22-phox (CYBA) are usually the 
rarest, accounting for fewer than 
10% of cases of CGD [12].
Morbidity due to infections re-
mains signiﬁcant, particularly in 
those with the X-linked type. Cur-
rently, the yearly mortality rate is 
a little more than 1.5% per year 
for persons with autosomal re-
cessive CGD and over 5% for 
those with X-linked CGD [10, 11]. 
The long-term survival rates of 
patients who present with symp-
toms after the end of their ﬁrst 
year of age is signiﬁcantly better 
than that of patients whose illness 
starts in infancy [13]. Fortunately, 
since the introduction of prophy-
lactic antibacterials and anti-fun-
gals the prognosis for patients 
with CGD has greatly improved, 
with patients frequently living to 
see their 30th and 40th birthdays 
[12, 13]. 
In our case and because of the 
detection of Clostridium difﬁcile 
in stool and Enterococcus faeca-
lis and Klebsiella pneumoniae in 
the excised cervical lymph node 
the patient was put on Metronida-
zole and Imipenem for 3 weeks. 
Following this treatment the pa-
tient’s condition has improved 
greatly and the degree of inﬂam-
mation (as monitored by the level 
of CRP and leukocyte count) has 
decreased. Although generally, 
the patient became better, nev-
ertheless, fresh blood spots were 
still noticeable in stools. Because 
nonspeciﬁc colitis was assumed 
to be associated with his condi-
tion, he was treated with oral 
prednisone at an initial dose of 1 
mg/kg body weight (BW). How-
ever, the two anal ﬁssures which 
were found on physical examina-
tion, might explain the fresh blood 
streaks of the stool in some of 
the instances. While in Germany, 
the patient was vaccinated with 
Pneumococcus vaccine and with 
the Measles, Mumps and Ru-
bella (MMR) a few months later. 
Therefore, with the previous vac-
cines he took (in Libya) his vac-
cination status is now considered 
complete. 
In view of the fact that patients 
with CGD usually have recurrent 
bactarial and fungal infections, 
which may lead to abscess forma-
tion in the skin, lymph nodes and 
viscera, our patient was put on a 
lifelong antibiotic (Cotrimoxazole, 
5mg TMP/kg BW) and antimy-
cotic (Itraconazole 10mg/kg BW) 
prophylaxis plan. Nevertheless,     www.ljm.org.ly   
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the patient was advised to have 
a regular liver function tests. The 
general condition of our patient 
is now satisfactory and is gain-
ing weight gradually. He is now 2 
years and 9 months of age. The 
last respiratory system examina-
tion revealed a clear chest with 
normally breathing lungs devoid 
of infections. His parents are 
pleased with the outcome of the 
treatment so far, and are con-
stantly monitoring his condition 
with regular follow-up visits to the 
hospital.
Alternative methods of treating 
CGD include interferon-gamma 
injections [14], white blood cells 
(WBC) infusions, and bone marrow 
transfusion (BMT) [15]. Gamma-
interferon, although widely used 
in the USA, in Europe it is usu-
ally preserved for the difﬁcult and 
persistent infections. The route of 
administration (an injection given 
twice weekly) is also a drawback. 
Transfusion of WBC from healthy 
donors is sometimes used but not 
preferred for its obvious side ef-
fects in the form of transfusion re-
actions that can occur especially 
after repeated transfusions. Gene 
therapy is also an option for CGD 
cases, where patients’ own stem 
cells are removed and the defec-
tive genes replaced with normal 
genes before reinjecting them 
back to the patient [16]. 
By presenting this typical case 
of CGD, the authors advise that 
primary immune deﬁciency dis-
eases, particularly CGD, should 
be considered in cases of chronic 
unresponsive infections, espe-
cially in children. After conﬁrming 
the diagnosis, all cases of CGD 
should be put on a life-long ag-
gressive antibiotic and antifungal 
prophylaxis treatment; and for in-
fections, special antibiotic and an-
tifungal therapy regimes should 
be started for periods up to 3 
times longer than that for patients 
with other similar conditions. Ear-
ly detection and treatment of such 
congenital disorders will certainly 
decrease the many complications 
that may arise in the course of the 
disease. Furthermore, CGD pa-
tients should have frequent and 
regular consultations with their 
health care providers, and have 
access to CGD resources for in-
formation in the form of booklets 
and websites dedicated to the 
disease [17]. 
Corresponding Author:
A A Al-Tubuly, MD, PhD,
Associate Professor of Immunology,
DMI, Faculty of Medicine, 
Alfateh University, Tripoli, Libya
Email: altubuly@dmi.lyLibyan Journal of Medicine, Volume 1, 2006
page
170
    www.ljm.org.ly   
ljm
REFERENCES
1. Zambrano E, Esper F, Rosenberg R, 
Kim J, Reyes-Mugica M. Chronic gran-
ulomatous disease. Pediatr Dev Pathol 
2003; 6(6): 577-81.
2. Richardson MP, Ayliffe MJ, Helbert 
M and Davies EG. A simple ﬂow cy-
tometry assay using dihydrorhodamine 
for the measurement of the neutrophil 
respiratory burst in whole blood: com-
parison with the quantitative nitroblue-
tetrazolium test. J Immunol Meth 1998; 
219 (1): 187-193.
3. Vowells SJ, Fleisher TA, Sekhsaria 
S, Alling, DW, Maquire, TE, Mallech, 
HL. Genotype-dependent variability in 
ﬂow cytometry evaluation of reduced 
nicotinamide adenine dinucleotide 
phosphate oxidase function on patients 
with chronic granulomatous disease. J 
Pediatrics 1996; 128 (1): 104-7
4. Vowells SJ, Sekhsaria S, Malech 
HL, Shalit M and Fleisher TA. Flow 
cytometric analysis of the granulocyte 
respiratory burst:a comparison study 
of ﬂuorescent probes. J Immunol Meth 
1995; 178 (1): 89-97
5. Gorman MR, Corrochano V. Rapid 
whole-blood ﬂow cytometry assay for 
diagnosis of chronic granulomatous 
disease. Clin Diagn Lab Immunol 1995; 
2: 227.
6. Heyworth PG, Cross AR, Curnutte 
JT. Chronic granulomatous disease. 
Curr Opin Immunol. 2003; (15): 578-
584.
7. Kostakoglu L, Hardoff R, Mirtcheva 
R, Goldsmith S. PET-CT Fusion Imag-
ing in Differentiating Physiologic from 
Pathologic FDG Uptake1. Radiograph-
ics 2004; (24): 1411-1431.
8. Kamani N. Chronic Granulomatous 
Disease, From Emedicine-webMD-
publications 2002; http://www.emedi-
cine.com/ped/topic1590.htm
9. Nowicki R. Chronic Granulomatoue 
Disease, From Emedicine-webMD-
publications, 2005; http://www.emedi-
cine.com/derm/topic719.htm
10. Agudelo-Fl¨®rez P, L¨®pez JA, 
Redher J, Cameiro-Samaio MM, Costa-
Carvalho BT, Grumach AS, Condino-
Neto A. The use of reverse transcrip-
tion-PCR for the diagnosis of X-linked 
chronic granulomatous disease. Braz J 
Med Biol Res 2004; 37(5): 625-34.
11. Ishibashi F, Nunoi H, Endo F. Statis-
tical and mutational analysis of chronic 
granulomatous disease in Japan with 
special reference to gp91-phox and 
p22-phox deﬁciency. Hum Genet 2000; 
106(5): 473-81.
12. Carnide EG, Jacob CA, Castro AM, 
Pastorino AC. Clinical and laboratory 
aspects of chronic granulomatous dis-
ease in description of eighteen patients. 
Ped Allerg Immunol 2005; 16(1): 5-9.
13. Ma JS, Chen PY, Fu LS, Chi CS, 
Huang YF, Lin CY, Shieh CC. Chronic 
granulomatous disease: a case report. 
J Microbiol Immunol Infect 2000; 33(2): 
118-22.
14. Bielorai B, Toren A, Wolach B, Man-
del M, Golan H, Neumann Y, Kaplinisky 
C, Weintraub M, Keller N, Amariglio 
N, Paswell J, Rechavi G. Success-
ful treatment of invasive aspergillosis 
in chronic granulomatous disease by 
granulocyte transfusions followed by 
peripheral blood stem cell transplan-
tation. Bone Marrow Transplant. 2000 
Nov; 26(9):1025-8.
15. Mamishi S, Zomorodian K, Saadat 
F, Gerami-Shoar M, Tarazooie B, Sia-
dati SA. A case of invasive aspergillo-
sis in CGD patient successfully treated 
with Amphotericin B and INF-gamma.     www.ljm.org.ly   
page
171
Libyan Journal of Medicine, Volume 1, 2006
ljm
Ann Clin Microbiol Antimicrob. 2005 
Mar 3; 4:4.
16. Ott MG, Schmidt M, Schwarzwaelder 
K, Stein S, Siler U, Koehl U, Glimm H, 
Kuhlcke K, Schilz A, Kunkel H, Naun-
dorf S, Brinkmann A, Deichmann A, 
Fischer M, Ball C, Pilz I, Dunbar C, Du 
Y, Jenkins NA, Copeland NG, Luthi U, 
Hassan M, Thrasher AJ, Hoelzer D, 
von Kalle C, Seger R, Grez M. Correc-
tion of X-linked chronic granulomatous 
disease by gene therapy, augmented 
by insertional activation of MDS1-EVI1, 
PRDM16 or SETBP1. Nat Med. 2006 
Apr; 12(4):401-9.
17. CGD–A guide for patients and fami-
lies. A short guide to CGD that answers 
common questions often asked by par-
ents and guardians of children with 
CGD, and by the children themselves. 
34 pages, published June 2003: http://
www.cgd.org.uk/downloads/CGD_
guide.pdf
www.ljm.org.ly